

Maternal medication and breastfeeding: Current recommendations.

Horn A, MBChB. DCH(SA). MRCP(Paed) (UK). FCPaed (SA). Cert Neon (SA)
Senior Specialist and Registered Neonatologist, Division of Neonatal Medicine, UCT

(SA Fam Pract 2005;47(9): 42-47)

Introduction

The benefits of breastfeeding for infants in the first year of life in developing countries¹ and developed countries² are well established. In addition, maternal benefits such as earlier return to pre-pregnant weight,³ increased child spacing,⁴ improved bone re-mineralization postpartum,⁵ reduction in hip fractures in the post-menopausal period,⁶ reduced risk of ovarian cancer,⁷ and pre-menopausal breast cancer,⁸ are well described. Thus a decision to deny the infant and mother the potential benefits of breast feeding must be carefully considered, and based on the best available evidence.

The average transfer of most medications into human milk is exceedingly low⁹ and there are very few instances when breast feeding is absolutely contraindicated. However, there are a number of medications where the available advice in national formularies is limited to manufacturer's cautionary statements to meet the minimum requirement of the licensing authority. Fortunately is research available to inform decisions regarding the use of these medications.

Available Resources

The short list of groups of agents that are commonly quoted as being contraindicated in breastfeeding is Cytotoxic agents, Radioactive compounds, Drugs of Abuse and Ergotamine. But, there are exceptions, additions, cautions and knowledge gaps. The most recent American Academy of Pediatrics (AAP) review, in 2001, has summarised most of the available evidence,¹⁰ but still leaves some areas open to variable interpretation. The AAP review also uses difficult descriptions such as, "Effect unknown but may be of concern" and "Usually compatible with breastfeeding".

There are several other reviews and monographs that provide more

detailed analysis and management.^{11-13,17,19, 20,21} The WHO published a document in 2003 that is freely available on the internet¹⁹, which comments specifically on the safety of drugs on the essential drugs list. The advice given is easier to follow than the AAP summary¹⁰. In addition, the Medicines Information Centre (MIC), University of Cape Town, has an on-line data base of drugs used in lactation²⁰. Both of these resources provide guidelines that are easier to follow than the AAP guidelines and the MIC data base explains the reasons for the levels of concern.

Other particularly useful on-line resources are:
<http://www.perinatology.com/exposures/druglist.htm>
<http://www.medsafe.govt.nz/Profs/P/Uarticles/lactation.htm>

Excretion of drugs in breast milk and subsequent effect in the infant

The milk:plasma (M:P) ratio describes the extent to which a drug is concentrated in breast milk, but the effect of this medication is ultimately determined by the amount of milk that the infant ingests and the therapeutic dose of the drug⁹. Thus, even drugs which are concentrated in breast milk, may be safe if the ultimate dose ingested is sub-therapeutic. If the dose (mg/kg/day) received by the infant (Relative Infant Dose, RID or Exposure Index, EI) is less than 10% of the therapeutic dose then it is safe unless the drug or its active metabolites accumulate.¹³ The RDI is thus directly proportional to the M:P ratio and inversely proportional to the rate of clearance of the drug by the infant⁹. Drugs with low rates of clearance will probably result in higher levels of exposure and drugs with high rates of clearance will result in a low level of exposure, even if the M:P ratio is high. Ito and Koren⁹ described this

relationship with the following equation:
$$RDI = [A \times (M:P \text{ ratio}/CL_1)] \times 100.$$

A = milk intake per Kg per minute, and
CL₁ = rate of drug clearance of the infant (ml/kg/minute).

Current Recommendations

Despite the available research quoted, regarding M:P ratios and RDIs, this information is of limited value as milk intake per kg varies from infant to infant and within the same infant with time.

Thus all infants should be monitored for adverse effects that are possible in their mothers, according to the package insert, this is particularly true of substances which have specific side effects such as sulphur drugs and antibiotics that may precipitate haemolysis with G6PD deficiency, and agents which are associated with allergic reactions, such as Quinine.

The following tables summarise medications, according to group, that are contra-indicated, or best avoided during breast feeding. Also included in the table are those agents where concern has been expressed by the AAP, but where sufficient research exists to proceed with breastfeeding (eg; Metoclopramide). Comment about the level of concern, effects and then alternatives is provided where available. Several comprehensive reviews^{10,13,17,19,20,21} formed the basis for this data and original source references are only quoted where they provide information not found in, or different to the main reviews consulted. The three most comprehensive data bases and their opinions (status) are shown for comparison.

This summary is not exhaustive and it must be remembered that even where avoidance is suggested, that the risks and benefits of breast feeding need to be weighed up. In addition, there are strategies available to minimise exposure: feed pre dosage and express milk during short courses. ♀

Table 1: Drugs that are generally contraindicated in Breastfeeding^{10,19,13,20}

Drug	MIC Status	AAP Status	WHO Status	Reason for concern/effect	Comment	Alternative / Recommendation
Cytotoxics and all other antineoplastic	C	C	C	The three agents below are mentioned specifically by the AAP. These, and all other Cytotoxics are listed and contraindicated in the WHO list during breast feeding because of potential immune suppression, neutropaenia, carcinogenesis and unknown effect on growth.		
Cyclophosphamide	C	C	C	Neonatal Neutropaenia reported ¹⁷		Contra-indicated
Doxorubicin	C	C	C	Possible immune suppression, carcinogenesis, neutropenia. Unknown side effects on growth. Cardiac toxicity and myelosuppression.M:P 4.4 ²¹		Contra-indicated
Methotrexate	C	C	C	M:P Ratio <0.1 RID 0.3%. ¹⁷ Low weekly doses used for arthritis are probably low risk for infant. ²¹		Mothers being treated with Methotrexate can make informed choice.
Drugs of Abuse						
Amphetamine	C	C	N	Irritability, poor sleeping pattern, Maternal lactation inhibition.	Concentrated in Breast milk. Detected in neonatal urine.	Contra-indicated
Cocaine	C	C	N	Seizures, withdrawal symptoms, Increased risk of sids	Methadone used for treatment of addiction is safe for breastfeeding infants at a maternal dose of up to 80mg/day ¹⁵	Contra-indicated Methadone is maternal drug of "choice" only if controlled.
Heroin/Morphine	C	C	N	Withdrawal symptoms	Morphine M:P 2.5	Opioids are NOT contraindicated with short-term therapeutic use.
Phencyclidine (PCP)	C	C	N	Potent hallucinogen ²¹	M:P >10 ¹⁷	Contra-indicated
Marijuana	C	C	N	May cause developmental delay ¹⁶	Minimal data available	Contra-indicated
Alcohol	AS	com	N	Inhibits milk ejection reflex. Excessive drinking causes lethargy and motor delay in the infant. ^{21, 11}	M:P 0.9 ³⁸	Occasional alcohol permissible, but avoid breastfeeding 1-2 hours after intake if possible.
Immune Suppressants						
Azathioprine	AS	N	C	Theoretical Immune suppression, neutropaenia. ²¹	RID 0.1% ¹⁷ No side effects in the 9 reported cases of exposure ¹³	Allow mothers to make informed choice based on reports. Monitor serum levels in mother and blood count in infant.
Cyclosporin	C	C	C	Theoretical Immune suppression, neutropaenia. ²¹	M:P=0.3 RID 0.04% ¹⁷ Recent report found levels in milk to be undetectable. ¹⁸ But other reports differ ²⁰	Contra-indicated until more data available.
Radioactive Compounds						All radioactive compounds are contraindicated
All radioactive compounds	C	C	C	Radioactivity persists in the milk for at least the half-life of the compound – in some cases (⁶⁷ Ga, ¹²⁵ I, ¹³¹ I) as long as 2 weeks. ¹⁰	Recommendations vary regarding recommendation of duration of cessation of breast feeding. ^{99m} Tc macroaggregates: safe to resume breast feeding after 24 hours ¹⁴ For other agents, safest practice is to monitor radioactivity in milk after each half life and resume breastfeeding when it is at background levels.	Express milk prior to exposure and resume breastfeeding when radioactivity levels are safe. Use agents with negligible radioactivity after the shortest period: ^{99m} Tc macroaggregates: safe to resume breast feeding after 24 hours ¹⁴ For other agents, safest practice is to monitor radioactivity in milk after each half life and resume breastfeeding when it is at background levels.

Key C: Contra-indicated, AS: Avoid if possible and monitor for side-effects, N: No comment, SEC: Significant effects reported, suggest caution, UNC: Unknown effect, but may be of concern, coms: usually compatible, but monitor for side effects, com: compatible with breast feeding.

Table 2: Drugs that should be avoided or may require careful infant monitoring.^{10,19,13,20}

Drug	MIC Status	AAP Status	WHO Status	Reason for concern/effect	Comment	Recommendation
Antiarrhythmic agents						
Amiodarone	C	UNC	N	Possible hypothyroidism ^{12,30}	RID 37% ³⁸ Long elimination half-life and high proportion of iodine contained in each dose ¹²	Amiodarone Contra-indicated, if exposure within months of breastfeeding³⁰
Procainamide	AS	com	coms	Concentrated in breast milk. Slowly eliminated from neonates. ¹¹	M:P 4, RID 5% ¹⁷	Agents of choice are: Digoxin, Lidocaine, Quinidine
Disopyramide, Flecainide, Mexiletine,	AS	OK	N	Limited Data ²¹		
Antibiotics						
Metronidazole (High Dose)	AS	UNC	AS	In vitro mutagen ²¹	M:P = 1, RID 10-20% ²¹	Stop breast feeding x 12h post high dose. Standard doses probably safe¹¹
Chloramphenicol	C	UNC	AS	Possible idiosyncratic marrow suppression – no reported cases ²¹	M:P 0.5	Contra-indicated¹¹
Tetracyclines	AS	coms	AS	Potential for staining teeth but negligible amounts in breastmilk – no reported cases ²¹	M:P 0.6 RID 4-6% ³⁸	Avoid, but short courses probably safe.¹³
Clindamycin, Quinolones, Aminoglycosides	AS	com	AS	These agents are found in breastmilk in very small amounts, and AAP deems breastfeeding to be compatible, but they should be avoided if alternative agents are available.		Antibiotics that are considered safe²⁰ are: Cephalosporins, Vancomycin, Macrolides, Penicillins, Trimethoprim
Sulfamethoxypyridazine	AS	N	N	High concentrations in breast milk. Haemolysis in G6PD def. infant. ^{11, 21}		Avoid
Anticholinergics						
Atropine	caution	com	coms	Possible anticholinergic effects in infant ²¹	No reported effects ¹⁰	Use with caution
Anticoagulants						
Phenindione	C	SEC	N	Anticoagulant effect in infant. ¹³	Phenindione not used in the US RID 15% ¹⁷	Phenindione Contra-indicated. Warfarin and Heparin are safe.
Anticonvulsants						
Ethosuximide	AS	UNC	AS	Poor feeding and sedation in all 3 of these agents. ¹³	RID > 10% ¹³	Recommended agents are: Phenytoin (but 1 case report of methaemoglobinemia), Valproic acid (but individual reports of hepatitis and marrow suppression), Clonazepam. There is insufficient data on the newer agents ^{26, 27} .
Phenobarbital	AS	SEC	coms			
Primidone	AS	SEC	N			
Carbamazepine	AS	UNC	CS	Previously thought to be safe but recent reports of poor feeding and cholestasis ²⁶	M:P 0.38 RID 2.8 – 7.3% ³⁸	Avoid if possible and monitor liver function in neonate.
Lamotrigine	AS	UNC	N	Potential therapeutic serum concentrations in infant. ²⁶	M:P 0.6, RID 23-33% No adverse effects in 5 reported infants. ²⁶	Avoid if possible Monitor for GI, haematological and dermatological adverse effects.
Antidepressants						
Lithium	C	SEC	AS	Plasma concentrations in infant may reach 50% of maternal levels and toxicity (apathy, restlessness, vomiting, diarrhoea, weakness) been reported. ³⁷	Few complications have been identified if mother's plasma levels are kept at 0.5mmol/L 12 hours after ingestion ¹⁷ .	Lithium should be avoided, but if breastfeeding is continued it is essential to monitor maternal serum levels and monitor infant for apathy, irritability, vomiting. Valproic acid is a safer alternative for mania ²⁴ .
Doxepin	C	UNC	N	Several reports of respiratory symptoms hypotonia & sedation. ^{13,23}	M:P 0.7-1.1 RID 0.8% ¹⁷ There are several more suitable alternatives.	Doxepin is Contraindicated. Recommended Tricyclic antidepressants include Amitriptyline, desipramine, nortryptoline and amoxapine. (RDI 1.5%) ²⁴
Fluoxetine	caution	SEC	N	Colic, sedation, irritability, diarrhoea ²³	M:P 0.3-0.5, RID 6-13% ¹⁷	Avoid Fluoxetine if possible. Recommended Selective Serotonin Reuptake inhibitors are Sertraline and Paroxetine. ²³

Drug	MIC Status	AAP Status	WHO Status	Reason for concern/effect	Comment	Recommendation
Antihistamines						
Clemastine	AS	SEC	N	One case of irritability, feeding difficulties, drowsiness and hyperexcitability. ²⁷	M:P 0.25 – 0.5 ¹⁷	Although the other antihistamines are generally considered safe, data is generally lacking. Terfenadine has been associated with irritability ²⁷ and Diphenhydramine is contraindicated by the manufacturer. Agent of choice is Loratidine ²⁸
Antihypertensives						
Atenolol	AS	SEC	AS	Hypotension and bradycardia reported ²¹	RIDs ²³ : Acebutolol: 3.5% Atenolol: 5.7 – 19.2%	Beta-blockers of choice are Labetolol and Propanolol ²¹ (RIDs: 0.07 & 0.9 respectively)
Alpha-blockers	AS	N	N	Indoramin and Prazosin are both excreted in breastmilk and no safety studies are available ³¹		Hydralazine appears to be safe but minimal data is available ²¹
Minoxidil	AS	com	N	Limited data ²¹		
Moxonidine	C	N	N	Concentrated in breastmilk ³¹		
Reserpine	AS	N	C	Increased secretions ²¹		Ca-channel blocker of choice is verapamil ²¹ . ACE inhibitors of choice are Enalapril, Captopril ²¹ .
Clonidine	AS	N	N	May decrease maternal prolactin ²¹		
Anti-inflammatories						
Aspirin High Dose	C/AS	SEC	N	1 case of metabolic acidosis ²¹		Central acting agent of choice is methyl dopa ²¹
Dipyrrone (NSAID)	AS	com	N	High concentrations in milk. Potential for agranulocytosis. ³³	Occasional doses probably safe ²¹ M:P 0.06 RID 3% ¹⁷ One report of cyanosis. ³³	Avoid salicylates if possible (due to possible idiosyncratic association with Reye's syndrome) Safe NSAIDs include: Diclofenac, Ibuprofen, Flurbiprofen, Ketorolac ²⁰
Gold Salts	AS	com	N	Potential nephritis & hepatitis 1 study showed higher infant dose than maternal dose. ³²	No actual reported side effects	Avoid or close monitoring of infant.
Phenylbutazone	AS	com	N	One case of seizures. Long half life ¹²	Minimal excretion in milk ¹² Side effects most unlikely.	Use other NSAIDs if possible
Antimalarials						
Mefloquine	C	N	C	Lack of data ²¹	M:P 0.15 RID 8% ¹⁷	Chloroquine and Quinine are safe, but allergy to Quinine possible ¹¹
Antimycobacterials						
Clotazimine	AS	UNC	coms	Reversible skin discoloration ²¹	Minimal Data	All common antituberculous drugs (Isoniazid, Rifampicin, pyrazinamide, ethambutol) are compatible with breast feeding as long as infant is monitored for jaundice. ¹⁹
Dapsone	AS	com	coms	Haemolytic anaemia ²¹ M:P 0.4 RID 20% ¹⁷	Avoid in Newborns and G6PD deficiency	
Cycloserine	AS	com	N	Concentrated in breast milk ²¹	Insufficient data	
Antithyroid Agents						
Carbimazole	NC	UNC	N	Neonatal Goitre ¹⁰	M:P 1-1.2 RID 3-12% ¹⁷	Propylthiouracil is a safe alternative ²¹
Antipsychotics						
Clozapine	C	UNC	N	Potential Agranulocytosis. ¹¹	RDI 1% , no reported side effects ¹⁷	Avoid Clozapine and Chlorpromazine. No agent is ideal, because of the potential for sedation, but the newer atypical agents, Risperidone and Olanzapine have a better side effect profile in adults, RDIs of 4.3 and 1.6% respectively and small short term studies show no infant side effects. Side effects have also not been present with Haloperidol, but developmental scores are lower ²⁴
Chlorpromazine	AS	UNC	AS	Reported to significantly increase sleep apnoea in neonates ²⁴		

Key C: Contra-indicated, AS: Avoid if possible and monitor for side-effects, N: No comment, SEC: Significant effects reported, suggest caution, UNC: Unknown effect, but may be of concern, coms: usually compatible, but monitor for side effects, com: compatible with breast feeding.

Table 2: Drugs that should be avoided or may require careful infant monitoring.^{10,19,13,20} (Continued)

Drug	MIC Status	AAP Status	WHO Status	Reason for concern/effect	Comment	Recommendation
Anxiolytics Diazepam, Alprazolam, Midazolam, Lorazepam	AS	UNC	AS	Long term chronic use causes sedation. ¹³	Short term, intermittent use is safe. RIDs vary: 0.7 - 2	Short term use (1-2 weeks) is usually safe, long term daily exposure should be avoided. ²⁴ Short acting agents preferred.
Diuretics Loop diuretics Long acting thiazide diuretics	AS	coms	N	May suppress lactation. Long-acting agents may accumulate. ²¹		Hydrochlorothiazide in low doses is safe although high doses may suppress lactation ²¹ Acetazolamide is safe.
Gastrointestinal agents Metoclopramide	com	UNC	AS	Increases maternal prolactin. Appears in the breast milk ³⁴ May increase maternal depression and seizures, and precipitate serotonin syndrome in women taking SSRIs. ⁴⁰	No side effects seen in infants of mother taking up to 45mg/day ³⁴ RID 4.7 – 11.3% ³⁸	Safe for infants and is still the recommended first line galactagogue in healthy mothers,³⁶ but it is contraindicated in mothers with phaeochromocytoma, a history of depression, psychiatric disorders, or seizures⁴¹. Domperidone has less CNS side effects and is an effective galactagogue ³⁹ .
Sulphasalazine Mesalazine	coms	SEC	AS	One case each of diarrhoea reported in the literature in infants of mothers taking this medication. ²¹	But studies have shown that insignificant amounts of Sulphasalazine are excreted in breast milk ²⁹ (RID 0.3- 0.6) ¹⁷ RID 6-10% ¹⁷	Sulphasalazine is probably safe but infant should be monitored for diarrhoea.
Hormonal Agents						
Ergotamine (antimigraine doses)	C	SEC	AS	Suppresses lactation. May cause convulsions ²¹		Contra-indicated
Bromocriptine	C	SEC	N	Suppresses lactation. Maternal strokes, seizures, hypertension and heart attacks reported. ²⁵	May still have a role suppressing lactation in non breastfeeding women but they must be informed of risks	Contra-indicated. Mothers who decide to nurse after receiving bromocriptine should probably wait up to one week before breast-feeding because of the long halflife. ²¹
Combined Contraceptive	AS	coms	AS	May inhibit lactation or cause gynaecomastia. ¹⁰		Oral Contraceptives should not be taken during the first six weeks post partum. Thereafter, the progestogen- only (minipill), Depot-medroxyprogesterone acetate or levonorgestrel implants are preferred methods. ^{21,11}
Cyproterone acetate	C	N	N	Concentrated in breast milk ¹¹		Contra-indicated
MAOIs - irreversible	C	N	N	Inhibited catecholamine metabolism	Eg: Moclobemide; M:P = 0.75 RID = 1.1% ²⁰	Contra-indicated²⁴ Probably Safe²⁰
MAOIs - reversible	PS	N	N			
Miscellaneous						
Bromide	AS	coms	N	Rash, Weakness ²¹		Avoid
Iodides and Iodine	C	coms	AS	Systemic, topical and vaginal povidone-iodine in nursing mothers results in elevated milk concentration and thyroid suppression in nursing infants. ²¹		Should not be used
Theophylline	caution	coms	com	Irritability been described ²¹	Significant infant exposure unlikely if maternal serum levels in the normal range ²¹	Keep maternal serum levels in normal range. Monitor infant.

Key C: Contra-indicated, AS: Avoid if possible and monitor for side-effects, N: No comment, SEC: Significant effects reported, suggest caution, UNC: Unknown effect, but may be of concern, coms: usually compatible, but monitor for side effects, com: compatible with breast feeding. PS: Probably safe

References

1. WHO collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. *Lancet* 355, 451 (2000).
2. American Academy of Pediatrics, Work Group on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics* 1997;100:1035-9.
3. Dewey KG, Heinig MJ, Nommsen LA. Maternal weight-loss patterns during prolonged lactation. *Am J Clin Nutr* 1993;58:162-166.
4. Kennedy KI, Visness CM. Contraceptive efficacy of lactational amenorrhoea. *Lancet*. 1992;339:227-230.
5. Melton LJ, Bryant SC, Wahner HW, et al. Influence of breastfeeding and other reproductive factors on bone mass later in life. *Osteoporos Int*. 1993;3:76-83.
6. Cumming RG, Klineberg RJ. Breastfeeding and other reproductive factors and the risk of hip fractures in elderly woman. *Int J Epidemiol* 1993;22:684-691.
7. Rosenblatt KA, Thomas DB, WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Int J Epidemiol*. 1993;22:192-197.
8. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer. *N Engl J Med*. 1994;330:81-87.
9. Ito S, Koren G. A novel index for expressing exposure of the infant to drug in breast milk. *Br J Clin Pharmacol* 1994;38:99-102.
10. American Academy of Paediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk. *Pediatrics* 2001;108:776-789 <http://www.pediatrics.org/cgi/content/full/108/3/776>
11. Bennett PN, ed. Drugs and human lactation. 2nd ed. Amsterdam: Elsevier, 1996.
12. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed. Baltimore: Williams & Wilkins, 1998.
13. Ito S. Drug therapy for breast-feeding women. *NEJM*. 2000; 343: 118-126.
14. Pittard WB, Merkatz R, Fletcher BD. Radioactive excretion in human milk following administration of Tc 99m macroaggregated albumin. *Pediatrics* 1982;70: 231-234.
15. Wojnar-Horton RE, Kristensen JH, Yapp P, Ilett KE, Dusci LJ, Hackett LP. Methadone distribution and excretion into breastmilk of clients in a methadone maintenance programme. *Br J Clin Pharmacol* 1997; 44: 543-7.
16. Astley SJ, Little RE. Maternal Marijuana use during lactation and infant development at one year. *Neurotoxicol Teratol* 1990; 12: 161-8.
17. Neonatal Formulary. The Northern Neonatal Network. 4th Ed. 2003. BMJ Books. www.neonatalformulary.com
18. Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. *Transplantation*. 1998;65:253-5.
19. WHO. Breast feeding and maternal medication. Recommendations for drugs in the eleventh WHO model list of essential drugs. 2003. http://www.who.int/child-adolescent-health/New_Publications/NUTRITION/BF_Maternal_Medication.pdf
20. Drug Use in Lactation on line Data Base. Medicines Information Centre, University of Cape Town. <http://www.mic.uct.ac.za/>
21. Anderson PO. Drug use during breast-feeding. *Clinical Pharmacy* Aug 1991; 10:594-614.
22. Steiner E, Villen T, Hallberg M, Rane A. Amphetamine secretion in breast milk. *Eur J Clin Pharmacol*. 1984;27:123-4.
23. Berlin CM, Briggs GG. Drugs and Chemicals in Human milk. *Seminars in Fetal and Neonatal Medicine*. 2005;10: 149-159.
24. Hale TW. Drug Therapy and Breastfeeding: Antidepressants, Antipsychotics, Antimanics and Sedatives. *Neoreviews*. 2004;5:451-456.
25. Morgans D. Bromocriptine and postpartum lactation suppression. *Br J Obstet Gynecol* 1995;102:851-853.
26. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: A review. *J Clin Psychiatry* Feb 2000;61(2):79-88.
27. Ilett KF, Kristensen JH, Wojnar-Horton RE & Begg EJ. Drug distribution in human milk. *Australian Prescriber* 1997;20(2):35-40.
28. Hilbert J, et al. Excretion of Loratidine in human breast milk. *J Clin Pharmacol* 1988;28:234-9.
29. Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. *Scand J Gastroenterol* 1979;14(7):869-71.
30. Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. *Am J Cardiol* 1998 Aug 20;82(4A):581-621.
31. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. *Clin Pharmacokinet* 1998 Jul;35(1):9-36.
32. Bennett PN, Humphries SJ, Osborne JP, Clarke AK, Taylor A. Use of sodium aurothiomalate during lactation. *Br J Clin Pharmacol* 1990 Jun;29(6):777-9.
33. Spigset O, Hägg S. Analgesics and Breast-feeding. *Paediatr Drugs* 2000 May-Jun;2(3):223-238.
34. Hagemann TM. Gastrointestinal medications and breastfeeding. *J Hum Lact* 1998 Sep;14(3):259-62.
35. Brown TE, et al. Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. *J Soc Gynecol Investig*. 2000 Jan-Feb;7(1):65-9.
36. Gabay MP. Galactagogues: medications that induce lactation. *J Hum Lact*. 2002 Aug;18(3):274-9.
37. Maitra R, Menkes DB. Psychotropic drugs and lactation. *The New Zealand Medical Journal*. June 1996;109(1024):217-219.
38. Gardiner S, Begg E. Prescriber Update. Drug Safety in Lactation. <http://www.medsafe.govt.nz/Profs/PUarticles/lactation.htm>
39. da Silva OP, et al. Effect of Domperidone on milk production in mothers of premature newborns. A randomized, double-blind, placebo controlled trial. *CMAJ* 2001;164: 17-21
40. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. *Ann Pharmacother*. 2002 Jan;36(1):67-71.
41. British National Formulary No. 49. March 2005. British Medical Association and the Royal Pharmaceutical Society of Great Britain.

Correspondence: Dr Alan Horn, Room 63, H46, Old Main Building, Groote Schuur Hospital, Observatory, Cape Town, 7925, South Africa, Tel: +27 21 4046024/25/69, Fax: +27 21 447 1660, Cell (SA): 082 4588544, E-mail: arhorn@uctgsh1.uct.ac.za

Masters degree in Clinical Pharmacology

MPharmMed

Acquire a critical and analytical approach to clinical pharmacology and advance your therapeutic reasoning and decision-making skills.

The MPharmMed course comprises a three year, part-time course and covers all aspects of clinical pharmacology, i.e. pharmacokinetics, pharmacodynamics, toxicology and medical biostatistics. It includes topics such as evidence-based medicine, pharmaco-economics and the critical appraisal of literature. A research project has to be completed to qualify by applying research methodology in the student's specific work environment. This degree will qualify you better for clinical research and open doors to other medical and pharmaceutical career opportunities.

The MPharmMed degree is presented by the Department of Pharmacology, University of Pretoria. It is unique in South Africa and has since 1974 provided a singular opportunity for doctors in all spheres of medicine to follow a formal course in Clinical Pharmacology. The popularity of this degree has grown over the years emphasising the importance of clinical pharmacology in modern medicine.

The course has recently been restructured into various modules that are also individually accredited for CPD purposes.

The next course starts on
1 February 2006.

For further information contact **Professor JR Snyman**,

Tel: (012) 319 2243, Fax: (012) 319 2411 or

write to the Department of Pharmacology,

School of Medicine, Faculty of Health Sciences,

P.O. Box 2034, Pretoria, 0001 or

e-mail: jbekker@medic.up.ac.za